Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 272

1.

Regressing to Prior Response Preference After Set Switching Implicates Striatal Dysfunction Across Psychotic Disorders: Findings From the B-SNIP Study.

Hill SK, Reilly JL, Ragozzino ME, Rubin LH, Bishop JR, Gur RC, Gershon ES, Tamminga CA, Pearlson GD, Keshavan MS, Keefe RS, Sweeney JA.

Schizophr Bull. 2014 Sep 5. pii: sbu130. [Epub ahead of print]

PMID:
25194139
[PubMed - as supplied by publisher]
2.

Detecting reliable cognitive change in individual patients with the MATRICS Consensus Cognitive Battery.

Gray BE, McMahon RP, Green MF, Seidman LJ, Mesholam-Gately RI, Kern RS, Nuechterlein KH, Keefe RS, Gold JM.

Schizophr Res. 2014 Aug 21. pii: S0920-9964(14)00389-2. doi: 10.1016/j.schres.2014.07.032. [Epub ahead of print]

PMID:
25156338
[PubMed - as supplied by publisher]
3.

Circadian rhythms in cognitive functioning among patients with schizophrenia: Impact on signal detection in clinical trials of potential pro-cognitive therapies.

Hufford MR, Davis VG, Hilt D, Dgetluck N, Geffen Y, Loebel A, Haig G, Santarelli L, Keefe RS.

Schizophr Res. 2014 Aug 6. pii: S0920-9964(14)00375-2. doi: 10.1016/j.schres.2014.07.018. [Epub ahead of print]

PMID:
25108773
[PubMed - as supplied by publisher]
4.

Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review.

Keefe RS, McClintock SM, Roth RM, Doraiswamy PM, Tiger S, Madhoo M.

J Clin Psychiatry. 2014 Aug;75(8):864-76. doi: 10.4088/JCP.13r08609.

PMID:
25099527
[PubMed - in process]
Free Article
5.
6.

Cognition and motivation as treatment targets in schizophrenia.

Keefe RS.

JAMA Psychiatry. 2014 Sep 1;71(9):987-8. doi: 10.1001/jamapsychiatry.2014.1281. No abstract available.

PMID:
25075711
[PubMed - in process]
7.

Resting-state brain function in schizophrenia and psychotic bipolar probands and their first-degree relatives.

Lui S, Yao L, Xiao Y, Keedy SK, Reilly JL, Keefe RS, Tamminga CA, Keshavan MS, Pearlson GD, Gong Q, Sweeney JA.

Psychol Med. 2014 May 20:1-12. [Epub ahead of print]

PMID:
25066779
[PubMed - as supplied by publisher]
8.

Refining the latent structure of neuropsychological performance in schizophrenia.

Lam M, Collinson SL, Eng GK, Rapisarda A, Kraus M, Lee J, Chong SA, Keefe RS.

Psychol Med. 2014 May 22:1-14. [Epub ahead of print]

PMID:
25066336
[PubMed - as supplied by publisher]
9.

Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia.

Marx CE, Lee J, Subramaniam M, Rapisarda A, Bautista DC, Chan E, Kilts JD, Buchanan RW, Wai EP, Verma S, Sim K, Hariram J, Jacob R, Keefe RS, Chong SA.

Psychopharmacology (Berl). 2014 Sep;231(17):3647-62. doi: 10.1007/s00213-014-3673-4. Epub 2014 Jul 17.

PMID:
25030803
[PubMed - in process]
10.

Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale.

Keefe RS, Davis VG, Spagnola NB, Hilt D, Dgetluck N, Ruse S, Patterson TD, Narasimhan M, Harvey PD.

Eur Neuropsychopharmacol. 2014 Jun 28. pii: S0924-977X(14)00177-1. doi: 10.1016/j.euroneuro.2014.06.009. [Epub ahead of print]

PMID:
25028065
[PubMed - as supplied by publisher]
11.

The Brief Assessment of Cognition In Affective Disorders (BAC-A):performance of patients with bipolar depression and healthy controls.

Keefe RS, Fox KH, Davis VG, Kennel C, Walker TM, Burdick KE, Harvey PD.

J Affect Disord. 2014 Sep;166:86-92. doi: 10.1016/j.jad.2014.05.002. Epub 2014 May 11.

PMID:
25012414
[PubMed - in process]
12.

The longitudinal course of cognitive impairment in schizophrenia: an examination of data from premorbid through posttreatment phases of illness.

Keefe RS.

J Clin Psychiatry. 2014;75 Suppl 2:8-13. doi: 10.4088/JCP.13065su1.02. Review.

PMID:
24919165
[PubMed - indexed for MEDLINE]
13.

The continuous performance test, identical pairs: norms, reliability and performance in healthy controls and patients with schizophrenia in Singapore.

Rapisarda A, Kraus M, Tan YW, Lam M, Eng GK, Lee J, Subramaniam M, Collinson SL, Chong SA, Keefe RS.

Schizophr Res. 2014 Jul;156(2-3):233-40. doi: 10.1016/j.schres.2014.04.016. Epub 2014 May 10.

PMID:
24819191
[PubMed - in process]
14.

Development of a virtual reality assessment of everyday living skills.

Ruse SA, Davis VG, Atkins AS, Krishnan KR, Fox KH, Harvey PD, Keefe RS.

J Vis Exp. 2014 Apr 23;(86). doi: 10.3791/51405.

PMID:
24798174
[PubMed - in process]
15.

Exploratory analysis of social cognition and neurocognition in individuals at clinical high risk for psychosis.

Yong E, Barbato M, Penn DL, Keefe RS, Woods SW, Perkins DO, Addington J.

Psychiatry Res. 2014 Aug 15;218(1-2):39-43. doi: 10.1016/j.psychres.2014.04.003. Epub 2014 Apr 12.

PMID:
24755041
[PubMed - in process]
16.

Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first-episode schizophrenia.

Graham KA, Keefe RS, Lieberman JA, Calikoglu AS, Lansing KM, Perkins DO.

Early Interv Psychiatry. 2014 Feb 24. doi: 10.1111/eip.12122. [Epub ahead of print]

PMID:
24612563
[PubMed - as supplied by publisher]
17.

Validation of the Persian version of the brief assessment of cognition in schizophrenia in patients with schizophrenia and healthy controls.

Mazhari S, Parvaresh N, Eslami Shahrbabaki M, Sadeghi MM, Nakhaee N, Keefe RS.

Psychiatry Clin Neurosci. 2014 Feb;68(2):160-6. doi: 10.1111/pcn.12107. Epub 2013 Oct 31.

PMID:
24552637
[PubMed - in process]
18.

A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia.

Umbricht D, Keefe RS, Murray S, Lowe DA, Porter R, Garibaldi G, Santarelli L.

Neuropsychopharmacology. 2014 Jun;39(7):1568-77. doi: 10.1038/npp.2014.17. Epub 2014 Jan 27.

PMID:
24549101
[PubMed - in process]
19.

Using climate-FVS to project landscape-level forest carbon stores for 100 years from field and LiDAR measures of initial conditions.

Gálvez FB, Hudak AT, Byrne JC, Crookston NL, Keefe RF.

Carbon Balance Manag. 2014 Feb 4;9(1):1. doi: 10.1186/1750-0680-9-1.

PMID:
24495313
[PubMed]
Free PMC Article
20.

Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder.

Madhoo M, Keefe RS, Roth RM, Sambunaris A, Wu J, Trivedi MH, Anderson CS, Lasser R.

Neuropsychopharmacology. 2014 May;39(6):1388-98. doi: 10.1038/npp.2013.334. Epub 2013 Dec 6.

PMID:
24309905
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk